Cantor Fitzgerald Reiterates Overweight on Lyra Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Lyra Therapeutics (NASDAQ:LYRA).
August 15, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Lyra Therapeutics (NASDAQ:LYRA).
An Overweight rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100